title: Thermostable cross-protective subunit vaccine against Brucella species.
abstract: A subunit vaccine candidate was produced from Brucella suis 145 (biovar 4; expressing both the A antigen of Brucella abortus and the M antigen of Brucella melitensis). The preparation consisted mostly of polysaccharide (PS; >90% [wt/wt]; both cell-associated PS and exo-PS were combined) and a small amount of protein (1 to 3%) with no apparent nucleic acids. Vaccinated mice were protected (these had a statistically significant reduction in bacterial colonization compared to that of unvaccinated controls) when challenged with representative strains of three Brucella species most pathogenic for humans, i.e., B. abortus, B. melitensis, and B. suis. As little as 1 ng of the vaccine, without added adjuvant, protected mice against B. suis 145 infection (5 × 10(5) CFU), and a single injection of 1 μg of this subunit vaccine protected mice from B. suis 145 challenge for at least 14 months. A single immunization induced a serum IgG response to Brucella antigens that remained elevated for up to 9 weeks. The use of heat (i.e., boiling-water bath, autoclaving) in the vaccine preparation showed that it was thermostable. This method also ensured safety and security. The vaccine produced was immunogenic and highly protective against multiple strains of Brucella and represents a promising candidate for further evaluation.
authors.affiliation: Defence Research and Development Canada (DRDC), Suffield Research Centre, Medicine Hat, Alberta, Canada John.Cherwonogrodzky@drdc-rddc.gc.ca.
authors.forename: John W
authors.initials: JW
authors.lastname: Cherwonogrodzky
authors.affiliation: Defence Research and Development Canada (DRDC), Suffield Research Centre, Medicine Hat, Alberta, Canada.
authors.forename: Nicole D
authors.initials: ND
authors.lastname: Barabé
authors.affiliation: Defence Research and Development Canada (DRDC), Suffield Research Centre, Medicine Hat, Alberta, Canada.
authors.forename: Michelle L
authors.initials: ML
authors.lastname: Grigat
authors.affiliation: Defence Research and Development Canada (DRDC), Suffield Research Centre, Medicine Hat, Alberta, Canada.
authors.forename: William E
authors.initials: WE
authors.lastname: Lee
authors.affiliation: Defence Research and Development Canada (DRDC), Suffield Research Centre, Medicine Hat, Alberta, Canada.
authors.forename: Robert T
authors.initials: RT
authors.lastname: Poirier
authors.affiliation: Defence Research and Development Canada (DRDC), Suffield Research Centre, Medicine Hat, Alberta, Canada.
authors.forename: Scott J
authors.initials: SJ
authors.lastname: Jager
authors.affiliation: Defence Research and Development Canada (DRDC), Suffield Research Centre, Medicine Hat, Alberta, Canada.
authors.forename: Bradley J
authors.initials: BJ
authors.lastname: Berger
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000097:blood*; D001428:Bacterial Vaccines / Q000276:immunology; D002002:Brucella / Q000276:immunology*; D002004:Brucella Vaccine / Q000276:immunology*; D002006:Brucellosis / Q000276:immunology* / Q000517:prevention & control*; D004195:Disease Models, Animal; D005260:Female; D051379:Mice; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000276:immunology; D022223:Vaccines, Subunit / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D001428:Bacterial Vaccines; D002004:Brucella Vaccine; D014613:Vaccines, Attenuated; D022223:Vaccines, Subunit